HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Arrigo Lessana Tomás A. Salerno Roxanne Deslauriers Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ede, M. Articles by Deslauriers, R. Search for Related Content PubMed PubMed Citation Articles by Ede, M. Articles by Deslauriers, R.

Ann Thorac Surg 1997;63:721-727
© 1997 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Beyond Hyperkalemia: ß-Blocker–Induced Cardiac Arrest for Normothermic Cardiac Operations

Institute for Biodiagnostics, National Research Council of Canada, Winnipeg, Canada; Service de Chirurgie Cardiovasculaire, Hôpital Européen de Paris "La Roseraie," Paris, France; and Division of Cardiovascular and Thoracic Surgery, State University of New York at Buffalo, Buffalo, New York

Accepted for publication October 11, 1996.

Background. Four experimental protocols were carried out to assess the ability of esmolol to induce and maintain reversible cardiac arrest under continuous normothermic (37°C) perfusion.

Methods and Results. In the first protocol, 8 perfused rat hearts were subjected to 20, 60, 90, and 120 minutes of esmolol arrest, after which positive and negative first derivative of pressure, heart rate, left ventricular developed pressure, and left ventricular end-diastolic pressure were evaluated. Arrest was achieved 45 to 60 seconds after beginning the infusion of esmolol. Mechanical arrest was achieved before electrical arrest. In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts. The concentrations of esmolol varied from 0.084 to 6.7 mmol/L and from 0.12 to 1.45 mmol/L in the rat and rabbit heart experiments, respectively. In the third protocol, the effects of 20 minutes of normothermic (37°C) ischemia on the function of isolated rat hearts perfused with esmolol-containing Krebs solution were compared with those using high-potassium (25 mmol/L) Krebs solution. Group A subjects (n = 9) received the ischemic injury after being perfused (and arrested) for 20 minutes with either esmolol or potassium (KCl, 25 mmol/L). Group B subjects (n = 10) received the same ischemic insult before being perfused with either esmolol or potassium. Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of ±dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009). Finally, the fourth protocol was done to evaluate the effects of esmolol in a clinically relevant experimental model. Pigs were divided into esmolol (n = 6) and potassium (n = 5) groups and subjected to normothermic cardiopulmonary bypass and a 1-hour period of cardiac arrest. Twenty minutes after stopping infusion of the cardioplegic agents, all animals were weaned off bypass. There were no statistically significant differences between the groups.

Conclusions. Esmolol hydrochloride can be used as effectively as potassium for inducing and maintaining predictable and reversible cardiac arrest during normothermic cardiac operations.

This article has been cited by other articles:

				M. Scorsin, A. Mebazaa, N. A. Attar, B. Medini, J. Callebert, R. Raffoul, R. Ramadan, J. M. Maillet, A. Ruffenach, F. Simoneau, et al. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1022 - 1029. [Abstract] [Full Text] [PDF]

				D. J. Chambers Mechanisms and alternative methods of achieving cardiac arrest Ann. Thorac. Surg., February 1, 2003; 75(2): S661 - 666. [Abstract] [Full Text] [PDF]

				R. Bessho and D. J. Chambers Myocardial protection: The efficacy of an ultra-short-acting {beta}-blocker, esmolol, as a cardioplegic agent J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 993 - 1003. [Abstract] [Full Text] [PDF]

				T. Yasuda, H. Kamiya, Y. Tanaka, and G. Watanabe Ultra-short-acting cardioselective beta-blockade attenuates postischemic cardiac dysfunction in the isolated rat heart Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 647 - 652. [Abstract] [Full Text] [PDF]

				A. Bel, L. P. Perrault, B. Faris, C. Mouas, J.-P. Vilaine, and P. Menasche Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations Ann. Thorac. Surg., July 1, 1998; 66(1): 148 - 152. [Abstract] [Full Text] [PDF]